Skip to main content

Table 2 Summary of initial antifungal treatment in patients with proven and suspected invasive candidiasis

From: Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study

Antifungal treatment SAT for proven invasive candidiasis
N = 291
SAT for suspected invasive candidiasis
N = 544
Monotherapy 287 (98.6 %) 541 (99.5 %)
 Polyenes 6 (2.1 %) 6 (1.1 %)
  Amphotericin B deoxycholate 0 3
  Liposomal amphotericin B 4 3
  Amphotericin B lipid complex 2 0
 Azoles 99 (34.5 %) 248 (45.8 %)
  Fluconazole 99 244
  Voriconazole 0 4
 Echinocandin 182 (63.4 %) 287 (53.0 %)
  Caspofungin 160 252
  Micafungin 20 34
  Anidulafungin 0 1
 Flucytosine 0 0
Combination therapy 4 3
 Liposomal amphotericin B and flucytosine 0 2
 Caspofungin and fluconazole 2 0
 Caspofungin and voriconazole 1 0
 Caspofungin and flucytosine 1 0
 Amphotericin B deoxycholate and micafungin 0 1
  1. The results are given as n (%)
  2. SAT systemic antifungal therapy